Improving blood clot prevention after cancer surgery
An Equity Focused Intervention to Improve Utilization of Guideline Concordant Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery
This study is testing whether teaching surgeons and using a decision support tool can help patients who have major cancer surgeries get better blood clot prevention medications.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of South Carolina Academic / other |
| Locations | 1 site (Charleston, South Carolina) |
| Trial ID | NCT06451003 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the use of medications that prevent blood clots in patients undergoing major cancer surgeries. It will implement a stepped-wedge randomized trial involving surgeon education and an electronic medical record-based decision support tool to promote adherence to guidelines for venous thromboembolism prophylaxis. The study will focus on surgeons performing abdominopelvic cancer surgeries at the Medical University of South Carolina and will assess the impact of these interventions on prescription rates and patient understanding of blood clot risks.
Who should consider this trial
Good fit: Ideal candidates for this study are patients undergoing abdominopelvic cancer surgeries such as esophagectomy, gastrectomy, and hysterectomy within the Medical University of South Carolina system.
Not a fit: Patients who have received therapeutic anticoagulation within 30 days prior to surgery or those with chronic kidney disease grade 3 or higher may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the incidence of venous thromboembolism in cancer surgery patients, improving their overall health outcomes.
How similar studies have performed: Other studies have shown success with similar educational and decision support interventions in improving adherence to clinical guidelines, suggesting a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
SURGEON CLUSTER Inclusion Criteria: * Surgeons performing cancer surgery within the Medical University of South Carolina (MUSC) system will be identified. Patients undergoing surgery for included cancers in the three hospitals will be identified using inclusion/exclusion criteria as follows. "Abdominopelvic cancer surgery" includes esophagectomy, gastrectomy, pancreatectomy, small bowel resection, colectomy, proctectomy, cystectomy, nephrectomy and hysterectomy / oophorectomy performed for a diagnosis of cancer as identified by Current Procedural Terminology (CPT) code and International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code. Exclusion Criteria: * We will exclude patients receiving preoperative therapeutic anticoagulation within 30 days preoperatively, patients initiating therapeutic anticoagulation postoperatively and patients with chronic kidney disease grade 3 or higher. Patients with postoperative length of stay 30 days or greater will be excluded as ePpx duration is for 30 days postoperative. PATIENT SURVEY Inclusion Criteria: * Patients undergoing surgery for included cancers in the three hospitals will be identified using inclusion/exclusion criteria as follows. "Abdominopelvic cancer surgery" includes esophagectomy, gastrectomy, pancreatectomy, small bowel resection, colectomy, proctectomy, cystectomy, nephrectomy and hysterectomy / oophorectomy performed for a diagnosis of cancer as identified by Current Procedural Terminology (CPT) code and International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code. Exclusion Criteria: * We will exclude patients receiving preoperative therapeutic anticoagulation within 30 days preoperatively, patients initiating therapeutic anticoagulation postoperatively and patients with chronic kidney disease grade 3 or higher. Patients with postoperative length of stay 30 days or greater will be excluded as extended pharmacologic venous thromboembolism duration is for 30 days postoperative. * Lack of survey response.
Where this trial is running
Charleston, South Carolina
- Medical University of South Carolina — Charleston, South Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Thomas Curran, MD MPH — Medical University of South Carolina
- Study coordinator: Thomas Curran, MD MPH
- Email: currant@musc.edu
- Phone: 843-876-4846
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.